In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease
Copyright policy )In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease
The clinical heterogeneity of Alzheimer’s disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau pathology, amyloid distribution, and hypometabolism in variants of Alzheimer’s disease using novel multimodal PET imaging techniques. Tau pathology was primarily observed in brain regions related to clinical symptoms and overlapped with areas of hypometabolism. In contrast, amyloid-β deposition was diffusely distributed over the entire cortex. Tau PET imaging may thus serve as a valuable biomarker for the localization of neuronal injury in vivo and may help to validate atypical subtypes of Alzheimer’s disease.
Male, metabolism [Amyloid beta-Peptides], tau Proteins, Neuropsychological Tests, diagnostic imaging [Cognition Disorders], pathology [Alzheimer Disease], Executive Function, pathology [Brain], Alzheimer Disease, Fluorodeoxyglucose F18, metabolism [Fluorodeoxyglucose F18], Humans, diagnostic imaging [Brain], etiology [Atrophy], Language Disorders, Amyloid beta-Peptides, pathology [Corticomedial Nuclear Complex], Corticomedial Nuclear Complex, etiology [Cognition Disorders], 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole, Brain, complications [Alzheimer Disease], metabolism [Carbolines], metabolism [tau Proteins], metabolism [Brain], Positron-Emission Tomography, Female, etiology [Language Disorders], Atrophy, Cognition Disorders, diagnostic imaging [Alzheimer Disease], Carbolines, ddc: ddc:610
Male, metabolism [Amyloid beta-Peptides], tau Proteins, Neuropsychological Tests, diagnostic imaging [Cognition Disorders], pathology [Alzheimer Disease], Executive Function, pathology [Brain], Alzheimer Disease, Fluorodeoxyglucose F18, metabolism [Fluorodeoxyglucose F18], Humans, diagnostic imaging [Brain], etiology [Atrophy], Language Disorders, Amyloid beta-Peptides, pathology [Corticomedial Nuclear Complex], Corticomedial Nuclear Complex, etiology [Cognition Disorders], 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole, Brain, complications [Alzheimer Disease], metabolism [Carbolines], metabolism [tau Proteins], metabolism [Brain], Positron-Emission Tomography, Female, etiology [Language Disorders], Atrophy, Cognition Disorders, diagnostic imaging [Alzheimer Disease], Carbolines, ddc: ddc:610
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).97 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!